Theradiag, French Cancer Institute Partner to Assess Pharmacogenomic Value of miRNA | GenomeWeb

NEW YORK (GenomeWeb News) – Theranostics and in vitro diagnostics firm Theradiag today announced a partnership with the Regional Cancer Institute of Montpellier in France to assess the role of microRNA in predicting response to therapies for colorectal cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.